ExenatidevsLiraglutide

Molecular Formula

C₁₈₄H₂₈₂N₅₀O₆₀S

Molecular Weight

4,187 Da

Half-Life

Byetta: ~2.4 hours (immediate-release); Bydureon: ~7 weeks effective duration via PLGA microsphere technology; Tmax ~2.1 hours (Byetta)

Bioavailability

65–75% after subcutaneous injection (Byetta); microsphere sustained release for Bydureon

CAS Number

183321-74-6

Molecular Formula

C₁₇₂H₂₆₅N₄₃O₅₁

Molecular Weight

3,751 Da

Half-Life

~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days

Bioavailability

~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety

CAS Number

204656-20-2

Common

• Nausea
• Vomiting and diarrhea
• Injection site nodules (Bydureon)
• Decreased appetite and constipation

Uncommon

• Hypoglycemia

Serious

• Acute pancreatitis
• Renal impairment

Common

• Nausea
• Diarrhea
• Vomiting
• Decreased appetite and headache

Uncommon

• Injection site reactions

Serious

• Acute pancreatitis
• Gallbladder disease

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Exenatide is an FDA-approved GLP-1 receptor agonist with post-market safety data spanning 15+ years, though some safety concerns have emerged. Nausea affects 30-45% of patients, dose-dependent and typically improves within 1-2 weeks but can lead to treatment discontinuation in 5% of patients. Pancreatitis risk, while rare (0.1-0.2%), is increased and contraindicated in patients with history of acute pancreatitis. Benign thyroid C-cell adenomas were seen in rats across all exenatide doses in a 104-week carcinogenicity study, but this appears only in the Nonclinical Toxicology section: the immediate-release label (Byetta) carries no boxed warning and does not contraindicate medullary thyroid cancer or MEN 2. That contraindication belonged to extended-release Bydureon, which no longer has a current US label. Acute kidney injury has been reported in 0.3-1% of patients, particularly with concurrent NSAID or ACE inhibitor use. Hypoglycemia risk is minimal when used as monotherapy but increases substantially when combined with insulin or sulfonylureas.

Contraindications

• xPrior serious hypersensitivity reaction to exenatide or any excipient
• xSevere renal impairment (eGFR <15 mL/min) or end-stage renal disease
• xExtended-release exenatide only (Bydureon, now withdrawn in the US): personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. The immediate-release label carries no such contraindication and no boxed warning.

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.

Contraindications

• xPersonal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings
• xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• xKnown hypersensitivity to liraglutide or any excipients
• xPregnancy (Saxenda indication) — contraindicated; effective contraception required